Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript

Page 2 of 2

Operator: [Operator Instructions]. Your next question comes from Joel Beatty with Baird. Your line is open.

Unidentified Analyst : Hi. This is Ben Baluch [ph] on for Joel Beatty. Thanks for taking the question. On the company’s plan to engage with the FDA, has that meeting been scheduled yet?

Camille Bedrosian: As we said, we’re moving swiftly to meet with the FDA based on the interim data of eight individuals out of the 12 in our HELIOS study. And when we have the information from our meeting, we certainly will share those with you.

Operator: Thank you. There are no further questions at this time. I’ll turn the call back to Mr. Klee.

Justin Klee: Thank you, operator, and thank you all for joining us on our call today and for your support. We hope you have a good day.

Operator: Thank you for attending Amylyx Pharmaceuticals’ First Quarter 2024 Earnings Conference Call. This concludes the call. You may now disconnect. Have a wonderful rest of your day.

Follow Amylyx Pharmaceuticals Inc.

Page 2 of 2